RU2016136527A - Улучшенные способы лечения васкуляризированных злокачественных опухолей - Google Patents
Улучшенные способы лечения васкуляризированных злокачественных опухолей Download PDFInfo
- Publication number
- RU2016136527A RU2016136527A RU2016136527A RU2016136527A RU2016136527A RU 2016136527 A RU2016136527 A RU 2016136527A RU 2016136527 A RU2016136527 A RU 2016136527A RU 2016136527 A RU2016136527 A RU 2016136527A RU 2016136527 A RU2016136527 A RU 2016136527A
- Authority
- RU
- Russia
- Prior art keywords
- molecule
- binding ability
- specific
- antibody
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (26)
1. Способ лечения васкуляризированной злокачественной опухоли, предусматривающий введение нуждающемуся в этом пациенту-реципиенту молекулы, характеризующейся связывающей способностью, которая является специфической в отношении В7-Н3, и молекулы, характеризующейся связывающей способностью, которая является специфической в отношении фактора клеточной поверхности или его рецептора, которые стимулируют опухолевый ангиогенез.
2. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении В7-Н3, представляет собой:
(A) антитело к В7-Н3;
(B) связывающий В7-Н3 фрагмент (А); или
(C) диатело, которое связывается с В7-Н3.
3. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении фактора клеточной поверхности или его рецептора, которые стимулируют опухолевый ангиогенез, представляет собой:
(A) антитело к VEGF или антагонист VEGF; или
(B) антитело к VEGFR или антагонист VEGFR.
4. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении В7-Н3:
A. конкурирует за связывание с В7-Н3 с антителами BRCA84D, BRCA69D или PRCA157; или
B. имеет три CDR тяжелой цепи и три CDR легкой цепи антитела BRCA84D, антитела BRCA69D или антитела PRCA157.
5. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении фактора клеточной поверхности или его рецептора, которые стимулируют опухолевый ангиогенез:
A. конкурирует за связывание с VEGF с бевацизумабом; или
B. имеет три CDR тяжелой цепи и три CDR легкой цепи бевацизумаба.
6. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении В7-Н3, представляет собой антитело к В7-Н3, имеющая:
(A) вариабельный домен легкой цепи, который содержит CDR1, CDR2 и CDR3 легкой цепи BRCA84D;
(B) вариабельный домен тяжелой цепи, который содержит CDR1 CDR2 и CDR3 тяжелой цепи BRCA84D; и
(C) область Fc, которая содержит замены: L235V, F243L, R292P, Y300L и P396L.
7. Способ по п. 6, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении В7-Н3, представляет собой гуманизированное антитело к В7-Н3, которое содержит:
(A) вариабельную легкую цепь, имеющую аминокислотную последовательность hBRCA84D-2 VL (SEQ ID NO: 69); и
(B) вариабельную тяжелую цепь, имеющую аминокислотную последовательность hBRCA84D-2 VH (SEQ ID NO: 79);
и указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении фактора клеточной поверхности или его рецептора, которые стимулируют опухолевый ангиогенез, представляет собой бевацизумаб.
8. Способ по любому из пп. 3-7, при котором указанную молекулу, характеризующуюся указанной связывающей В7-Н3 способностью, и указанную молекулу, характеризующуюся указанной связывающей VEGF способностью, вводят указанному пациенту, и указанные две молекулы вводят одновременно.
9. Способ по п. 8, при котором вторую из указанных вводимых молекул вводят указанному пациенту не позднее 5 периодов полужизни после введения первой из указанных молекул.
10. Способ по любому из пп. 1 и 2, при котором указанная васкуляризированная злокачественная опухоль представляет собой глиобластому.
11. Способ по п. 1, при котором указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении В7-Н3, и указанная молекула, характеризующаяся указанной связывающей способностью, которая является специфической в отношении фактора клеточной поверхности или его рецептора, которые стимулируют опухолевый ангиогенез, представляют собой одну и ту же молекулу, причем указанная молекула представляет собой биспецифическое антитело или биспецифическое диатело.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939804P | 2014-02-14 | 2014-02-14 | |
| US61/939,804 | 2014-02-14 | ||
| PCT/US2015/015320 WO2015123241A1 (en) | 2014-02-14 | 2015-02-11 | Improved methods for the treatment of vascularizing cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016136527A true RU2016136527A (ru) | 2018-03-19 |
| RU2016136527A3 RU2016136527A3 (ru) | 2018-10-04 |
| RU2692248C2 RU2692248C2 (ru) | 2019-06-24 |
Family
ID=53800571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016136527A RU2692248C2 (ru) | 2014-02-14 | 2015-02-11 | Улучшенные способы лечения васкуляризированных злокачественных опухолей |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10100115B2 (ru) |
| EP (1) | EP3104880B1 (ru) |
| JP (1) | JP6533534B2 (ru) |
| KR (1) | KR20160135190A (ru) |
| CN (1) | CN106604740A (ru) |
| AU (1) | AU2015217278B2 (ru) |
| BR (1) | BR112016018754A2 (ru) |
| CA (1) | CA2939556A1 (ru) |
| IL (1) | IL247267A0 (ru) |
| MX (1) | MX2016010505A (ru) |
| RU (1) | RU2692248C2 (ru) |
| SG (1) | SG11201606714TA (ru) |
| WO (1) | WO2015123241A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PT2542256T (pt) * | 2010-03-04 | 2019-09-05 | Macrogenics Inc | Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| NZ747029A (en) | 2016-04-15 | 2025-05-02 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| WO2017214322A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN110624137B (zh) * | 2019-10-28 | 2022-07-01 | 易浦润（上海）生物技术有限公司 | 一种子宫支架 |
| US20230287090A1 (en) * | 2020-09-02 | 2023-09-14 | The Feinstein Institutes For Medical Research | USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19 |
| CN112574306B (zh) * | 2020-12-17 | 2023-05-05 | 武汉华美生物工程有限公司 | 脂联素单克隆抗体、抗体对及其制备方法和用途 |
| CN115887450B (zh) * | 2022-12-09 | 2024-06-25 | 杭州师范大学 | 角鲨烯化替莫唑胺的合成及其自组装纳米粒的制备和应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| EP0359096B1 (en) | 1988-09-15 | 1997-11-05 | The Trustees Of Columbia University In The City Of New York | Antibodies having modified carbohydrate content and methods of preparation and use |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| US5390540A (en) | 1992-01-31 | 1995-02-21 | Akron Special Machinery, Inc. | Control apparatus for the uniformity machine |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| DE69233739D1 (de) | 1992-10-28 | 2008-08-07 | Genentech Inc | Verwendung von Antagonisten des Zellwachstumsfaktors VEGF |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| CA2190101A1 (en) | 1994-05-13 | 1995-11-23 | Donald Leonard Nicholas Cardy | Improvements in or relating to peptide delivery |
| AU4755696A (en) | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| ATE427966T1 (de) | 1997-02-11 | 2009-04-15 | Immunomedics Inc | Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
| AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7109292B2 (en) | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1242401B1 (en) | 1999-11-24 | 2006-12-27 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2423843A1 (en) | 2000-10-18 | 2002-04-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| EP1450857B1 (en) | 2001-10-16 | 2010-09-15 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
| BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| PT1565489E (pt) | 2002-06-19 | 2011-02-23 | Raven Biotechnologies Inc | Anticorpos internalizantes específicos para o alvo de superfície celular raag10 |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CA2436368A1 (en) | 2003-08-01 | 2005-02-01 | Lorne Canvin | Footwear and insole therefor |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| JP2007536932A (ja) | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| AU2005270918B2 (en) | 2004-08-03 | 2011-03-03 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| CA2618681C (en) | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| CA2644903A1 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
| EP2021029B1 (en) | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| AU2007325872B2 (en) | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| US7992748B2 (en) | 2006-11-17 | 2011-08-09 | North Safety Products, Inc. | Earplug dispenser |
| KR20100014527A (ko) | 2007-03-22 | 2010-02-10 | 슬로안-케테링인스티튜트퍼캔서리서치 | 단일클론항체 8ｈ9의 용도 |
| CN101821288A (zh) | 2007-06-21 | 2010-09-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
| US7622656B2 (en) | 2007-08-20 | 2009-11-24 | Bayer Cropscience Ag | Cotton variety 05Y063 |
| LT2786762T (lt) | 2008-12-19 | 2019-06-10 | Macrogenics, Inc. | Kovalentiniai diakūnai ir jų panaudojimas |
| EA016172B1 (ru) * | 2009-05-26 | 2012-02-28 | Общество С Ограниченной Ответственностью "Онкомакс" | Способ подавления роста опухоли путем блокирования рецептора фактора роста фибробластов и способ диагностики злокачественных новообразований |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PT2542256T (pt) * | 2010-03-04 | 2019-09-05 | Macrogenics Inc | Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização |
| EP2882454B1 (en) * | 2012-08-07 | 2018-10-10 | F.Hoffmann-La Roche Ag | Combination therapy for the treatment of glioblastoma |
| US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SG11201609912TA (en) * | 2014-05-29 | 2016-12-29 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
-
2015
- 2015-02-11 WO PCT/US2015/015320 patent/WO2015123241A1/en active Application Filing
- 2015-02-11 JP JP2016569557A patent/JP6533534B2/ja not_active Expired - Fee Related
- 2015-02-11 KR KR1020167024816A patent/KR20160135190A/ko not_active Ceased
- 2015-02-11 SG SG11201606714TA patent/SG11201606714TA/en unknown
- 2015-02-11 CA CA2939556A patent/CA2939556A1/en not_active Abandoned
- 2015-02-11 RU RU2016136527A patent/RU2692248C2/ru not_active IP Right Cessation
- 2015-02-11 CN CN201580019620.2A patent/CN106604740A/zh active Pending
- 2015-02-11 AU AU2015217278A patent/AU2015217278B2/en not_active Expired - Fee Related
- 2015-02-11 EP EP15748950.1A patent/EP3104880B1/en active Active
- 2015-02-11 BR BR112016018754A patent/BR112016018754A2/pt not_active Application Discontinuation
- 2015-02-11 MX MX2016010505A patent/MX2016010505A/es unknown
- 2015-02-11 US US15/118,010 patent/US10100115B2/en not_active Expired - Fee Related
-
2016
- 2016-08-14 IL IL247267A patent/IL247267A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015123241A1 (en) | 2015-08-20 |
| CN106604740A (zh) | 2017-04-26 |
| US20170008961A1 (en) | 2017-01-12 |
| IL247267A0 (en) | 2016-09-29 |
| JP2017506669A (ja) | 2017-03-09 |
| JP6533534B2 (ja) | 2019-06-19 |
| KR20160135190A (ko) | 2016-11-25 |
| EP3104880A4 (en) | 2017-10-18 |
| CA2939556A1 (en) | 2015-08-20 |
| SG11201606714TA (en) | 2016-09-29 |
| RU2692248C2 (ru) | 2019-06-24 |
| AU2015217278A1 (en) | 2016-09-01 |
| EP3104880A1 (en) | 2016-12-21 |
| AU2015217278B2 (en) | 2020-03-19 |
| US10100115B2 (en) | 2018-10-16 |
| BR112016018754A2 (pt) | 2017-10-10 |
| RU2016136527A3 (ru) | 2018-10-04 |
| MX2016010505A (es) | 2017-04-13 |
| EP3104880B1 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016136527A (ru) | Улучшенные способы лечения васкуляризированных злокачественных опухолей | |
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| JP2013538057A5 (ru) | ||
| JP2017506067A5 (ru) | ||
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| AR108067A1 (es) | Moléculas de unión y métodos de uso de los mismos | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| AR109298A1 (es) | Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso | |
| JP2014503189A5 (ru) | ||
| FI3922645T3 (fi) | Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja | |
| JP2014503188A5 (ru) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| JP2014526898A5 (ru) | ||
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| JP2017529838A5 (ru) | ||
| JP2014158469A5 (ru) | ||
| RU2013152960A (ru) | Анти-cd40-антитела и способы применения | |
| JP2014509510A5 (ru) | ||
| JP2016536322A5 (ru) | ||
| JP2012254092A5 (ru) | ||
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| JP2014534237A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20210212 |